YILIMART - CD94-FITC, human, REAL287, 30 tests

Clone REAL287 is an antibody fragment derived from the full CD94 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.

Clone REAL287 recognizes CD94, an approximately 45 kDa, single-pass, type II transmembrane protein, which belongs to C-type lectin superfamily. CD94 associates covalently with NKG2 family members and forms disulfide bonded heterodimers. CD94-NKG2 receptors bind HLA-E, the non-classical MHC class Ib molecule. Depending on the associated NKG2 member, CD94-NKG2 heterodimer transmits either activating or inhibitory signal. For, e.g, via immunoreceptor tyrosine based-inhibitory motifs (ITIMs) containing NKG2A, CD94-NKG2A heterodimers inhibit NK cell cytotoxicity. Besides NK cells, expression of CD94-NKG2 heterodimers is also shown on NK-T cells and a small percentage of CD8 cells in mice, where the crosslinking of CD94-NKG2 was shown to reduce the level of spontaneous apoptosis.

The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

KLRD1, Kp43

Technical specifications

Antigen: CD94
Clone: REAL287
Isotype control: REAL Control
Alternative names of antigen: KLRD1, Kp43
Distribution of antigen: NK cells
Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
Storage: Store protected from light at 2–8 °C. Do not freeze.
Available conjugates: FITC, APC

Figure 1

Human peripheral blood mononuclear cells (PBMCs) were stained with REAlease CD94-APC (B) or with the corresponding REAL Control (A). REAlease CD94-APC was released using the REAlease Release Reagent (C). To show epitope accessibility after REAlease Complex release, the cells were washed with the REAlease Stop Reagent and restained with REAlease CD94-APC (D). Cells were labeled with CD56 antibodies in addition and analyzed by flow cytometry using the MACSQuant

^®

Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

A:	B:

C:	D:

Figure 2

Human peripheral blood mononuclear cells (PBMCs) were stained with REAlease CD94 Complexes or with the corresponding REAL Control (left images) as well as with CD56 antibodies and analyzed by flow cytometry using the MACSQuant

^®

Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide (PI) fluorescence.

Selected references
1. Brooks, A. G. et al. (1997) NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 185: 795-800
2. Braud, V. M. et al. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391(6669): 795-799
3. Gunturi, A. et al. (2003) Preferential survival of CD8 T and NK cells expressing high levels of CD94. J. Immunol. 170: 1737-1745
4. Wolpert, F. et al. (2015) Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS One 10(10): e0139603
5. Canté-Barrett, K. et al. (2017)
  
  Loss of CD44
  ^dim
  expression from early progenitor cells marks T-cell lineage commitment in the human thymus.
  
  Front Immunol 8: 32

查看数据文件查看下载

CD94-FITC, human, REAL287, 30 tests

For research use only

您浏览过的商品

Alternative names

Technical specifications

Figure 1

Figure 2

Selected references

相关产品